Incidence of prostate cancer in male breast cancer patients: A risk factor for prostate cancer screening

Prostate Cancer and Prostatic Diseases

Volumn 12, Issue 1, 2009, Pages 52-56

  Lee, U J ^a   Jones, J S ^a  

^a LERNER RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIANDROGEN; ANTINEOPLASTIC AGENT; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; PROGESTERONE RECEPTOR; PROSTATE SPECIFIC ANTIGEN; TAMOXIFEN;

AGED; ARTICLE; BREAST CANCER; CANCER INCIDENCE; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER SCREENING; COMORBIDITY; CONTROLLED STUDY; EXTERNAL BEAM RADIOTHERAPY; HISTOPATHOLOGY; HUMAN; MAJOR CLINICAL STUDY; MALE; MASTECTOMY; MEDICAL RECORD REVIEW; PREDICTION; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATECTOMY; PROTEIN EXPRESSION; RISK FACTOR; WATCHFUL WAITING;

AGED; AGED, 80 AND OVER; BREAST NEOPLASMS, MALE; HUMANS; INCIDENCE; MALE; MASS SCREENING; NEOPLASMS, MULTIPLE PRIMARY; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; RECEPTOR, ERBB-2; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; RETROSPECTIVE STUDIES; RISK FACTORS;

EID: 60349085078     PISSN: 13657852     EISSN: 14765608     Source Type: Journal    
DOI: 10.1038/pcan.2008.26     Document Type: Article

References (39)

1. Jemal A. Cancer statistics 2002. Can Cancer J Clin 2002; 52: 23-47.
2. Ravandi-Kashani F, Hayes TG. Male breast cancer: A review of the literature. Eur J Cancer 1998; 34: 1341-1347.
3. Ewertz M, Holmberg L, Karjalainen S, Treth S, Adami HO. Incidence of male breast cancer in Scandinavia, 1943-1982. Int J Cancer 1989; 43: 27-31.
4. Devesa SS, Blot WJ, Stone BJ, Miller BA, Tarone RE, Fraumeni Jr JF. Recent cancer trends in the United States. J Natl Cancer Inst 1995; 87: 175-182.
5. Ojara EA. Carcinoma of the male breast in Mulago Hospital, Kampala. East Afr Med J 1978; 55: 489-491.
6. Bhagwandin S. Carcinoma of the male breast in Zambia. East Afr Med J 1972; 49: 176-179.
7. Fentiman IS, Fourquet A, Hortobagyi GN. Male breast cancer [published erratum appears in Lancet 2006; 367: 1818]. Lancet 2006; 367: 595-604.
8. Waterhouse J, Muir C, Correa P, Powell JR (eds) Cancer Incidence in Five Continents, Vol 3. IARC Science Publications, 1976.
9. Steinitz R, Katz L, Ben-Hur M. Male breast cancer in Israel: Selected epidemiological aspects. J Med Sci 1981; 17: 816-821.
10. Satram-Hoang S, Ziogas A, Anton-Culver H. Risk of second primary cancer in men with breast cancer. Breast Cancer Res 2007; 9: R10; e-pub ahead of print January 25 2007.
11. Sherif M, Ibrahim AS, El-Aaser AA. Prostatic carcinoma in Egypt: epidemiology and etiology. Scand J Urol Nephrol Suppl 1980; 55 25-26.
12. Sobin LH, Sherif M. Relation between male breast cancer and prostate cancer. J Cancer 1980; 42: 787.
13. Allen FJ, Van Velden DJ. Prostate carcinoma metastatic to male breast. Br J Urol 1991; 67: 424-435.
14. Gough DB, Donohue JH, Evans MM, Pernicone PJ, Wold LE, Naessens JM et al. A 50 year experience of male breast cancer: Is outcome changing? Surg Oncol 1993; 2: 325-333.
15. Sasco AJ, Lowenfels AB, Pasker-de Jong P. Review article: Epidemiology of male breast cancer. A meta-analysis of published case-control studies and discussion of selected etiologic factors. Int J Cancer 1993; 53: 538-549.
16. Hultborn R, Hanson C, Köpf I, Verbiené I, Warnhammar E, Weimarck A. Prevalence of Klinefelter's syndrome in male breast cancer patients. Anticancer Res 1997; 17: 4293-4297.
17. Thomas DB, Jimenez LM, McTiernan A, Rosenblatt K, Stalsberg H, Stemhagen A et al. Breast cancer in men: Risk factors with hormonal implications. Am J Epidemiol 1992; 135: 734-748.
18. Schlappack OK, Braun O, Maier U. Report of two cases of male breast cancer after prolonged estrogen treatment for prostatic carcinoma. Cancer Detect Prev 1986; 9: 319-322.
19. Calabresi E, De Giuli G, Becciolini A, Giannotti P, Lombardi G, Serio M. Plasma estrogens and androgens in male breast cancer. J Steroid Biochem 1976; 7: 605-609.
20. Ballerini P, Recchione C, Cavalleri A, Moneta R, Saccozzi R, Secrete G. Hormones in male breast cancer. Tumori 1990; 76: 26-28.
21. Mabuchi K, Bross DS, Kessler II. Risk factors in male breast cancer. J Natl Cancer Inst 1985, 929-930.
22. Díez 0, Cortés J, Domènech M, Pericay C, Brunet J, Alonso C et al. BRCA2 germ line mutations in Spanish male breast cancer patients. Ann Oncol 2000; 11: 81-84.
23. Thorlacius S, Tryggvadottir L, Olafsdottir GH, Jonasson JG, Ogmundsdottir HM, Tulinius H et al. Linkage of BRCA2 region in hereditary male breast cancer. Lancet 1995; 346: 544-545.
24. Friedman LS, Gayther SA, Kurosaki T, Gordon D, Noble B, Casey G et al Mutation analysis of BRCA1 and BRCA2 in a male breast cancer population. Am J Hum Genet 1997; 60: 313-319.
25. Sigurdsson S, Thorlacius S, Tomasson J, Tryggvadottir L, Benediktsdottir K, Eyfjörd JE et al. BRCA2 mutation in Icelandic prostate cancer patients. J Mol Med 1997; 75: 758-761.
26. Edwards SM, Kote-Jarai Z, Meitz J, Hamoudi R, Hope Q, Osin P, et al. Cancer Research UK/British Prostate Group UK Familial Prostate Cancer Study Collaborators; British Association of Urological Surgeons Section of Oncology. Two percent of men with early-onset prostate cancer harbor germline mutations in the BRCA2 gene. Am J Hum Genet 2003; 72: 1-12; e-pub ahead of print 9 December 2002.
27. Gayther SA. The frequency of germ-line mutations in the breast cancer predisposition genes BRCA1 and BRCA2 in familial prostate cancer. The Cancer Research Campaign/British Prostate Group United Kingdom Familial Prostate Cancer Study Collaborators. Cancer Res 2000; 60: 4513-4518.
28. Tryggvadóttir L, Vidarsdóttir L, Thorgeirsson T, Jonasson JG, Olafsdóttir EJ, Olafsdóttir GH et al. Prostate cancer progression and survival in BRCA2 mutation carriers. J Natl Cancer Inst 2007; 99: 929-935; e-pub ahead of print 12 June 2007.
29. Bergen PI, Wong GY, Vlamis V, Potter C, Hoffmann B, Kinne DW et al Current management of male breast cancer: A review of 104 cases. Ann Surg 1992; 215: 451-459.
30. Jaiyesimi IA, Buzdar AU, Sahin AA, Ross MA. Carcinoma of the male breast. Ann Intern Med 1992; 117: 771-777.
31. Meijer-van Gelder ME, Look MP, Bolt-de Vries J, Peters HA, Klijn JG, Foekens JA. Clinical relevance of biologic factors in male breast cancer. Breast Cancer Res Treat 2001; 68: 249-260.
32. Terris MK, McCallum SW. Aromatase inhibitors for male infertility. J Urol 2002; 168: 1509.
33. Bardin A. Loss of ERbeta expression as a common step in estrogen-dependent tumor progression. Endocr Relat Cancer 2004; 11: 537-551.
34. Risbridger G, Wang H, Young P, Kurita T, Wang YZ, Lubahn D et al. Evidence that epithelial and mesenchymal estrogen receptor-alpha mediates effects of estrogen on prostatic epithelium. Dev Biol 2001; 229: 432-442.
35. Leibowitz SB, Garber JE, Fox EA, Loda M, Kaufman DS, Kantoff PW et al Male patients with diagnoses of both breast cancer and prostate cancer. Breast J 2003; 9: 208-212.
36. Thellenberg C, Malmer B, Tavelin B, Grönberg H. Second primary cancers in men with prostate cancer: An increased risk of male breast cancer. J Urol 2003; 169: 1345-1348.
37. Karlsson CT, Malmer B, Wiklund F, Gronberg H. Breast cancer as a second primary in patients with prostate cancer - estrogen treatment or association with family history of cancer? J Urol 2006; 176: 538-543.
38. American Cancer Society. Surveillance research 2006 based on cancer in North America, vol. 1, 1998-2002.
39. Pelzer AE, Tewari A, Bektic J, Berger AF, Frauscher F, Bartsch G et al. Detection rates and biologic significance of prostate cancer with PSA less than 4.0 ng/mL: Observation and clinical implications from Tyrol screening project. Urology 2005; 66: 1029-1033.